Schrodinger Inc
$ 11.80
4.42%
25 Feb - close price
- Market Cap 869,244,000 USD
- Current Price $ 11.80
- High / Low $ 12.00 / 11.46
- Stock P/E N/A
- Book Value 4.36
- EPS -2.40
- Next Earning Report 2026-03-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.16 %
- ROE -0.46 %
- 52 Week High 27.63
- 52 Week Low 11.11
About
Schrdinger, Inc. provides a physics-based software platform that enables the discovery of novel molecules for drug development and material applications. The company is headquartered in New York, New York.
Analyst Target Price
$25.44
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-06 | 2025-04-29 | 2025-02-26 | 2024-11-12 | 2024-07-31 | 2024-05-01 | 2024-02-28 | 2023-11-01 | 2023-08-02 | 2023-05-04 | 2023-02-28 |
| Reported EPS | -0.45 | -0.59 | -0.64 | -0.24 | -0.5233 | -0.74 | -0.76 | -0.41 | -0.86 | 0.06 | 1.75 | -0.38 |
| Estimated EPS | -0.71 | -0.8 | -0.81 | -0.38 | -0.6 | -0.85 | -0.75 | -0.38 | -0.71 | -0.47 | 1.31 | -0.53 |
| Surprise | 0.26 | 0.21 | 0.17 | 0.14 | 0.0767 | 0.11 | -0.01 | -0.03 | -0.15 | 0.53 | 0.44 | 0.15 |
| Surprise Percentage | 36.6197% | 26.25% | 20.9877% | 36.8421% | 12.7833% | 12.9412% | -1.3333% | -7.8947% | -21.1268% | 112.766% | 33.5878% | 28.3019% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-04 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.195 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SDGR
2026-02-26 19:52:36
Schrodinger Inc. (SDGR) reported Q4 2025 revenues of $87.2 million, slightly beating estimates, but its stock fell 2.89% after market open. Despite declining year-over-year revenue and gross profit, and an operating loss, the company recorded a positive net income and diluted EPS of $0.44, significantly above estimates. Insider trading showed five sales in the last six months, and while 95 institutional investors added shares, 143 decreased their positions.
2026-02-26 15:52:36
Schrodinger (NASDAQ:SDGR) shares gapped up after reporting better-than-expected earnings, with EPS of $0.44 against a consensus estimate of ($0.13) and revenue of $87.24 million. Despite surpassing estimates, the company remains unprofitable with a negative net margin and return on equity. Wall Street analysts currently hold a "Hold" consensus rating with an average price target of $24.33, while institutional investors show increased holdings in the stock.
2026-02-26 01:54:04
Schrödinger (SDGR) reported a 23% increase in total revenue for 2025, reaching $256 million, and maintains a strong cash position of $402 million. The company is shifting towards a throughput-based licensing model to enhance future revenue streams, despite facing challenges such as a negative operating margin and insider selling. Valuation metrics suggest the stock may be undervalued, with technical indicators showing it is oversold, potentially presenting a buying opportunity.
2026-02-25 22:40:00
Schrödinger (SDGR) announced strong Q4 and full-year 2025 earnings, surpassing revenue forecasts with $87.2 million against an anticipated $83.65 million. The company's stock rose 4.42% in aftermarket trading, reflecting investor confidence in its strategic transition to a hosted revenue model and strong drug discovery performance. Schrödinger also outlined its ambition to achieve positive adjusted EBITDA by the end of 2028, driven by sustained software ACV growth, increased hosted adoption, and disciplined expense management.
2026-02-25 07:54:04
Schrödinger, Inc. (SDGR) is highlighted as a compelling opportunity in the healthcare sector, known for its physics-based computational platforms in molecular discovery. Analysts show overwhelmingly positive sentiment with an average target price suggesting a 126.78% potential upside, despite the company currently being in a growth phase with negative EPS and free cash flow. Investors are advised to consider the stock's innovative edge, strategic partnerships, and technical indicators which suggest a balanced entry point for long-term returns.
2026-02-25 03:54:04
Schrödinger, Inc. (Nasdaq: SDGR) announced its participation in three investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference, the Leerink Global Healthcare Conference 2026, and the KBCM Healthcare Forum. Management will participate in fireside chats at each event, which will be accessible via their website's "Investors" section. Schrödinger, founded in 1990, uses its computational platform for molecular discovery in drug development and materials design, serving pharmaceutical and academic institutions globally.
